Countdown to the EU HTA: how can we seize this opportunity to improve patient access to medicines?

In January 2025, the EU HTA Regulation will become a reality: all new cancer medicines and advanced therapy medicinal products (ATMPs) will be jointly assessed at the EU level. The new EU HTA presents a significant opportunity for Europe to speed up access to new treatments. But only if we find a workable solution for a truly European assessment of the best available evidence, which can facilitate national decisions on access for these innovations.